menu
    • menu
    [{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CT-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CT-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CPT-6281","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Polpharma","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Polpharma \/ Ryvu Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"Molecure","sponsor":"Ocean Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"OAT-3912","moa":"YKL-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecure \/ Ocean Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Ocean Biomedical"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polpharma

                            Poland
                            ChemOutsourcing
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ryvu Therapeutics

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ryvu Therapeutics Enters into Two Agreements with Zakłady Farmaceutyczne Polpharma S.A. in the Area of RVU120...

                            Details : RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.

                            Product Name : RVU120

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 07, 2023

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ryvu Therapeutics

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            Polpharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Molecure

                            Poland arrow
                            Pharmex
                            Not Confirmed

                            Molecure

                            Poland arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OAT-3912

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ocean Biomedical

                            Deal Size : $32.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ocean Biomedical Pens $32M Pact for Polish YKL-40 Inhibitors

                            Details : Under the agreement, Ocean Biomedical gains the exclusive rights to further research, develop, manufacture and commercialize Molecure’s OAT-3912 and other selective YKL-40 inhibitors worldwide.

                            Product Name : OAT-3912

                            Product Type : Other Large Molecule

                            Upfront Cash : $0.6 million

                            October 15, 2024

                            Lead Product(s) : OAT-3912

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ocean Biomedical

                            Deal Size : $32.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Captor Therapeutics

                            Poland arrow
                            Pharmex
                            Not Confirmed

                            Captor Therapeutics

                            Poland arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Captor Therapeutics Announces Molecular Targets of CT-01 Program Developing TPD Therapy for Hepatocellular Car...

                            Details : Compelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit, and another undisclosed neo-substrate with essential function in tumorigenesis.

                            Product Name : CT-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 04, 2022

                            Lead Product(s) : CT-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Captor Therapeutics

                            Poland arrow
                            Pharmex
                            Not Confirmed

                            Captor Therapeutics

                            Poland arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPT-6281

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies ...

                            Details : CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC).

                            Product Name : CPT-6281

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 08, 2022

                            Lead Product(s) : CPT-6281

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Captor Therapeutics

                            Poland arrow
                            Pharmex
                            Not Confirmed

                            Captor Therapeutics

                            Poland arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Car...

                            Details : Strong and comparable efficacy was demonstrated with CT-01 candidate, also confirming the potent antitumor activity in a liver cancer mouse xenograft model and no treatment-related toxicity was observed.

                            Product Name : CT-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 13, 2022

                            Lead Product(s) : CT-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            WPD Pharmaceuticals

                            Poland arrow
                            Pharmex
                            Not Confirmed

                            WPD Pharmaceuticals

                            Poland arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berubicin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors

                            Details : The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2020

                            Lead Product(s) : Berubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth